Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
June 19, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 19, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against C3.ai, Inc. (NYSE: AI),...
Bragar Eagel & Squire, P.C. Is Investigating Fox, Ascendis, and Shift4 and Encourages Investors to Contact the Firm
April 28, 2023 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fox Corporation (NASDAQ:...
ASND INVESTOR NEWS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ascendis Pharma Investors to Inquire About Securities Class Action Investigation – ASND
April 11, 2023 18:45 ET
|
The Rosen Law Firm PA
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Ascendis...
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
November 14, 2019 16:01 ET
|
Ascendis Pharma
- Reflects company values and commitment to patients living with hypoparathyroidism - - Top-line data from expanded PaTH Forward Trial expected in first quarter of 2020 - - Company expects to exceed...
Ascendis Pharma A/S Announces Presentations on Achondroplasia and TransCon™ CNP at International Skeletal Dysplasia Society Meeting
September 12, 2019 16:20 ET
|
Ascendis Pharma A/S
– TransCon CNP program gains momentum with initiation of phase 2 ACcomplisH Trial – – Presentations provide new estimate of global birth prevalence and highlight quality-of-life impact of...
Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results
August 28, 2019 16:01 ET
|
Ascendis Pharma A/S
– TransCon hGH moves towards Biologics License Application submission following completion of heiGHt and fliGHt Trials – – Global reach of endocrinology rare disease programs expands – – Conference...
Ascendis Pharma A/S Announces Participation in August Investor Conferences
July 29, 2019 08:00 ET
|
Ascendis Pharma A/S
COPENHAGEN, Denmark, July 29, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical...